Just reviewing some of the rhetoric this management team released as news to investors. Did they shelve the renal research as well, like the other sais to be potent epigenetic molecules?...Its been so long I forget what became of this program. Its odd they didnt say they could raise the dead with their 7 year advanced research around epigenetics. I wonder while we have sat on our hands the past 5 years do we now have a 12 year lead in epigenetics??...I bet DMcC will tell investors we do!!,,,,no wonder we have no investor interest and the market clearly sees us as being a third world investment !

" 2016" "

"Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies."

"The Company now plans to initiate a Phase 2 Renal Impairment trial that is expected to commence in early 2017 based on the PK data confirmed in the Phase 1 trial."

"This new trial has been initiated and designed in accordance with the Company's strategy to expand into new indications such as renal (chronic kidney disease) and orphan diseases with its lead candidate, apabetalone. With continued success, this trial has the potential to create incremental value for apabetalone in new high-risk patient segments which have shorter development paths to product registration and market adoption."